Summary: A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Top Publications

  1. Maciejewska Paszek I, Grochowska Niedworok E, Siwiec A, Gruenpeter A, Dul L, Irzyniec T. Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis. J Int Med Res. 2017;45:525-532 pubmed publisher
    Objective To assess possible changes in leptin and ghrelin secretion due to etanercept in juvenile idiopathic arthritis (JIA)...
  2. Doll F, Schwager K, Hemmerle T, Neri D. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther. 2013;15:R138 pubmed publisher
    b>Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1, which is often used for the treatment of patients with rheumatoid arthritis...
  3. Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Puppo F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16:1173-1179 pubmed publisher
    ..b>Etanercept is a decoy receptor" for TNF-? and it is composed of two p75 TNF-? receptors fused to human IgG1...
  4. Garber C, Creighton Smith M, Sorensen E, Dumont N, Gottlieb A. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review. J Drugs Dermatol. 2015;14:881-6 pubmed
    ..Methotrexate (MTX) was the most frequently prescribed systemic (70%), followed by etanercept (59%)...
  5. Anink J, Nusman C, van Suijlekom Smit L, van Rijn R, Maas M, van Rossum M. Automated determination of bone age and bone mineral density in patients with juvenile idiopathic arthritis: a feasibility study. Arthritis Res Ther. 2014;16:424 pubmed publisher
    ..In total, 69 patients with standard hand radiographs at the start of etanercept treatment and of calendar age within the reliability ranges (2...
  6. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15:R67 pubmed
    ..This is the first report on continuous treatment with the TNF? fusion protein etanercept over seven years (y). Overall, 26 patients with active AS were initially treated with etanercept 2 × 25 mg s.c...
  7. Ahmadzadeh A, Daraei M, Jalessi M, Peyvandi A, Amini E, Ranjbar L, et al. Hearing status in patients with rheumatoid arthritis. J Laryngol Otol. 2017;131:895-899 pubmed publisher
    ..Sensorineural hearing loss was significantly more prevalent in patients who used azathioprine, cyclosporine and etanercept. Higher bone conduction thresholds in some frequencies were detected in rheumatoid arthritis patients that were ..
  8. Kubo S, Iwata S, Saito K, Tanaka Y. Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine. 2011;78:535-6 pubmed publisher
  9. Wambier C, Foss Freitas M, Paschoal R, Tomazini M, Simão J, Foss M, et al. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009;60:883-5 pubmed publisher

More Information


  1. Ikonomidis I, Papadavid E, Makavos G, Andreadou I, Varoudi M, Gravanis K, et al. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis. Circ Cardiovasc Imaging. 2017;10: pubmed publisher
    ..were randomized to receive an anti-IL-12/23 (ustekinumab, n=50), anti-tumor necrosis factor-a (TNF-α; etanercept, n=50), or cyclosporine treatment (n=50)...
  2. Gupta Ganguli M, Cox K, Means B, Gerling I, Solomon S. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes?. Diabetes Care. 2011;34:e121 pubmed publisher
  3. Santos J, Vendramini D, Nery J, Avelleira J. Etanercept in erythema nodosum leprosum. An Bras Dermatol. 2017;92:575-577 pubmed publisher
    ..A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept ..
  4. . Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. Prescrire Int. 2009;18:202-4 pubmed
    ..agents are acceptable for severe disease: methotrexate, then ciclosporin, and possible a TNF alpha antagonist (etanercept, etc...
  5. Solovey A, Somani A, Belcher J, Milbauer L, Vincent L, Pawlinski R, et al. A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. Am J Hematol. 2017;92:1119-1130 pubmed publisher
    ..Involvement of TNF was identified by beneficial impact from TNF blockers, etanercept and infliximab, with less benefit from an IL-1 blocker, anakinra...
  6. Mead A, Neo W, Barkas N, Matsuoka S, Giustacchini A, Facchini R, et al. Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation. J Exp Med. 2017;214:2005-2021 pubmed publisher
    ..These findings, which establish that Flt3-ITD-driven myeloproliferation results in cell-extrinsic suppression of the normal HSC reservoir, are of relevance for several aspects of acute myeloid leukemia biology. ..
  7. Krasselt M, Baerwald C, Wagner U, Rossol M. CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther. 2013;15:R139 pubmed publisher
  8. Li Q, Yu Q, Na R, Liu B. Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosis. Braz J Med Biol Res. 2017;50:e5868 pubmed publisher
    We aimed to investigate the effect of etanercept, a tumor necrosis factor-? (TNF-?) inhibitor, on rat cardiomyocyte hypertrophy and its underlying mechanism. Primary neonatal rat cardiomyocytes were isolated from Sprague-Dawley rats...
  9. Schoffelen T, Kampschreur L, van Roeden S, Wever P, den Broeder A, Nabuurs Franssen M, et al. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNF? therapy. Ann Rheum Dis. 2014;73:1436-8 pubmed publisher
  10. Detrez I, Van Steen K, Segaert S, Gils A. The association between etanercept serum concentration and psoriasis severity is highly age-dependent. Clin Sci (Lond). 2017;131:1179-1189 pubmed publisher
    The association between etanercept serum concentration and psoriasis disease severity is poorly investigated, and currently etanercept serum concentration monitoring that is aiming to optimize the psoriasis treatment lacks evidence...
  11. Bouman C, van Herwaarden N, van den Hoogen F, van der Maas A, van den Bemt B, den Broeder A. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Expert Opin Drug Metab Toxicol. 2017;13:597-604 pubmed publisher
    ..RA patients that were using adalimumab (n = 42), etanercept (n = 76) or infliximab (n = 51) and were doing well, were tapered until discontinuation or flare (1-1...
  12. Comte C, Guilhou J, Guillot B, Dereure O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology. 2008;217:284-5 pubmed publisher
  13. Winthrop K, Lebwohl M, Cohen A, Weinberg J, Tyring S, Rottinghaus S, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302-309 pubmed publisher
    ..One hundred thirty (3.6%) patients on tofacitinib (IR 2.55), no patients on placebo, and 2 using etanercept (IR 2.68) developed HZ...
  14. Vermeer M, Kuper H, Bernelot Moens H, Hoekstra M, Posthumus M, van Riel P, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14:R254 pubmed publisher
    ..The recommendations regarding T2T were successfully implemented and high adherence was observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice. ..
  15. Zhao Y, Yang R, Xiao M, Guan M, Zhao N, Zeng T. Kupffer cells activation promoted binge drinking-induced fatty liver by activating lipolysis in white adipose tissues. Toxicology. 2017;390:53-60 pubmed publisher
    ..This study was designed to investigate the roles of KCs inhibitor (GdCl3) and TNF-? antagonist (etanercept) on binge drinking-induced liver steatosis and to explore the underlying mechanisms...
  16. Couderc M, Mathieu S, Dubost J, Soubrier M. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol. 2013;40:1931-3 pubmed publisher
  17. Mehta P, Svahn J, Davies S, Pang Q, Harris R, Ghezzi P, et al. Etanercept treatment in Fanconi anaemia; combined US and Italian experience. Br J Haematol. 2012;158:809-11 pubmed publisher
  18. Egeth M, Soosaar J, Nash P, Choquette D, Infante R, Ramey D, et al. Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study. Adv Ther. 2017;34:1157-1172 pubmed publisher
    Brenzys was developed as an etanercept biosimilar of Enbrel...
  19. Tack C, Kleijwegt F, van Riel P, Roep B. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia. 2009;52:1442-4 pubmed publisher
  20. Jiang Y, Lin O, Sinha S. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci. 2017;62:1597-1606 pubmed publisher
    ..The majority of providers are either uncertain about or actively avoid use of anti-TNF? medications for those with HF. The risks and benefits of anti-TNF? use in HF patients must be investigated further. ..
  21. Petersen B, Lorentzen H. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab. Acta Derm Venereol. 2008;88:523-4 pubmed publisher
  22. Singh J, Hossain A, Mudano A, Tanjong Ghogomu E, Suarez Almazor M, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657 pubmed publisher
    ..To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (..
  23. Tanaka M, Sakai R, Koike R, Harigai M. Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents. J Rheumatol. 2015;42:1726-8 pubmed publisher
  24. Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada N, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77:855-862 pubmed publisher
    ..Patients (N = 1346) were randomized 2:2:2:1 to 80 mg ixekizumab every 2 or 4 weeks, 50 mg etanercept twice weekly, or placebo...
  25. Gonzalo Garijo M, Rodríguez Nevado I, Pérez Calderón R, Sánchez Vega S, Pérez Rangel I. Severe cutaneous reaction and fever due to adalimumab. Ann Allergy Asthma Immunol. 2010;105:490-1 pubmed publisher
  26. Durham L, Taams L, Kirkham B. Psoriatic arthritis. Br J Hosp Med (Lond). 2016;77:C102-8 pubmed publisher
  27. Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli Richard C, Berenbaum F, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 2014;16:481 pubmed publisher
    ..The aim of the SPARSE study was to evaluate the effects of the anti-tumor necrosis factor agent etanercept on NSAID intake and conventional clinical outcomes in axSpA patients...
  28. Kaltsonoudis E, Zikou A, Voulgari P, Konitsiotis S, Argyropoulou M, Drosos A. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125 pubmed publisher
    ..The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis factor (TNF) ? antagonists...
  29. Hmamouchi I, Costes V, Combe B, Morel J. Scurvy as the presenting illness of Whipple's disease exacerbated by treatment with etanercept in a patient with ankylosing spondylitis. J Rheumatol. 2010;37:1077-8 pubmed publisher
  30. Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, et al. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017;69:1590-1598 pubmed publisher
    To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active nonradiographic axial spondyloarthritis (SpA)...
  31. de Giorgi V, Benemei S, Grazzini M, Lotti T, Geppetti P. Rapid growth of Merkel cell carcinoma during etanercept treatment of psoriatic arthritis: cause or coincidence?. Acta Derm Venereol. 2011;91:354-5 pubmed publisher
  32. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, et al. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol. 2012;41:490-1 pubmed publisher
  33. Uhlig T, Goll G. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49-iv62 pubmed publisher
    ..Additional ongoing studies and registries may help to optimize the process of switching, and different funding models are examining the optimal mechanisms to ensure effective uptake of these new treatments. ..
  34. Ruiz Argüello B, del Agua A, Torres N, Monasterio A, Martinez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med. 2013;51:e287-9 pubmed publisher
  35. Meusch U, Klingner M, Baerwald C, Rossol M, Wagner U. Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition. Arthritis Res Ther. 2013;15:R219 pubmed
    ..were determined in vitro in monocytes from 20 RA patients prior to initiation of therapeutic TNF inhibition with etanercept, and the subsequent clinical response was monitored...
  36. Weiß A, Song I, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther. 2014;16:R35 pubmed publisher
    ..reported outcomes (PRO) and objective inflammation in patients with axial spondylarthritis (SpA) treated with etanercept (ETA) or adalimumab (ADA)...
  37. Wigerblad G, Huie J, Yin H, Leinders M, Pritchard R, Koehrn F, et al. Inflammation-induced GluA1 trafficking and membrane insertion of Ca2+ permeable AMPA receptors in dorsal horn neurons is dependent on spinal tumor necrosis factor, PI3 kinase and protein kinase A. Exp Neurol. 2017;293:144-158 pubmed publisher
  38. Matos T, O Malley J, Lowry E, Hamm D, Kirsch I, Robins H, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing ?? T cell clones. J Clin Invest. 2017;127:4031-4041 pubmed publisher
    ..These cells likely represent the disease-initiating pathogenic T cells in psoriasis, suggesting that lasting control of this disease will require suppression of these resident T cell populations...
  39. Rahman N, Healy C, Flint S, Stassen L. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. J Clin Rheumatol. 2010;16:197-9 pubmed publisher
  40. Moots R, Xavier R, Mok C, Rahman M, Tsai W, Al Maini M, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE. 2017;12:e0175207 pubmed publisher
    ..of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug ..
  41. Rodríguez Angulo H, Garcia O, Castillo E, Cardenas E, Márques J, Mijares A. Etanercept induces low QRS voltage and autonomic dysfunction in mice with experimental Chagas disease. Arq Bras Cardiol. 2013;101:205-10 pubmed publisher
    ..This study aimed to determine the effects of a soluble TNF-? agonist, etanercept, on electrocardiographic parameters in the acute phase of experimental infection with Trypanosoma cruzi...
  42. Turina M, Yeremenko N, Paramarta J, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16:413 pubmed publisher
    ..Results were validated in ankylosing spondylitis (AS) with infliximab (cohort 2, n?=?21) and peripheral SpA with etanercept (cohort 3, n?=?20). Serum levels of calprotectin, hs-CRP, PTX-3, VEGF (all P?<?0.001) and MMP-3 (P?=?0...
  43. Ofer Shiber S, Molad Y. Elevated C-Reactive Protein Level Predicts Earlier Treatment with Tumor Necrosis Factor-Alpha Inhibitors in Psoriatic Arthritis. Isr Med Assoc J. 2016;18:279-82 pubmed
    ..003, HR 2.62, 95% CI 0.393-2.5). In patients with psoriatic arthritis, CRP ? 0.9 mg/dl at diagnosis significantly predicts an earlier need for a TNF inhibitor to achieve disease control. ..
  44. Bouman C, van Herwaarden N, van den Hoogen F, Fransen J, van Vollenhoven R, Bijlsma J, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017;76:1716-1722 pubmed publisher
    ..Safety and efficacy of disease activity guided TNFi DR in RA are maintained up to 3?years, with a large reduction in TNFi use, but no other benefits. Implementation of DR would vastly improve the cost-effective use of TNFi. ..
  45. Ibrahim F, Lorente Cánovas B, Doré C, Bosworth A, Ma M, Galloway J, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology (Oxford). 2017;56:2004-2014 pubmed publisher
    ..The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response...
  46. Fleischmann R, Kavanaugh A, Smolen J. Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology (Oxford). 2013;52:409-10 pubmed publisher
  47. Kinoshita Y, Saeki H. A Review of the Active Treatments for Toxic Epidermal Necrolysis. J Nippon Med Sch. 2017;84:110-117 pubmed publisher
    ..There is still much to be investigated regarding the pathogenesis of TEN, and new findings may contribute to the identification of an effective active intervention strategy. ..
  48. Peper S, Lew R, Mikuls T, Brophy M, Rybin D, Wu H, et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. Arthritis Care Res (Hoboken). 2017;69:1467-1472 pubmed publisher
    ..the durability of triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) versus methotrexate-etanercept in RA...
  49. Bansback N, Phibbs C, Sun H, O Dell J, Brophy M, Keystone E, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Ann Intern Med. 2017;167:8-16 pubmed publisher
    The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients with active rheumatoid arthritis (RA)...
  50. Shi X, Zhou W, Huang H, Zhu H, Zhou P, Zhu H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care. 2013;17:R301 pubmed publisher
    ..In this study, the commercially available TNF-? inhibitor etanercept was used to inhibit TNF-? induced by lethal A/FM/1/47 (H1N1) influenza virus infection of mice...
  51. Almon E, Khoury T, Drori A, Gingis Velitski S, Alon S, Chertkoff R, et al. An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. J Immunol Methods. 2017;446:21-29 pubmed publisher
    ..The PRX-106 may provide a safe orally administered effective anti-TNF alpha-based immune therapy for inflammatory bowel diseases and non-alcoholic steatohepatitis, as well as other autoimmune, TNF-mediated diseases. ..